Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease

García-Bournissen, Facundo; Moroni, Samanta; Marson, María Elena; Moscatelli, Guillermo; Mastrantonio, Guido; Bisio, Margarita; Cornou, Laura; Ballering, Griselda; Altcheh, Jaime

doi:10.1136/archdischild-2014-306358

Cited by 31 publications

(23 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent and serious are cutaneous, neurologic, hepatic, and hematologic. Anti-parasitic therapy is contraindicated in pregnancy, but may be offered during breastfeeding if indicated [95,96]. Other contraindications include renal or hepatic insufficiency and advanced cardiomyopathy (Figure 9).…”

Section: Anti-trypanosomal Treatment During the Chronic Phasementioning

confidence: 99%

WHF IASC Roadmap on Chagas Disease

et al. 2020

View full text Add to dashboard Cite

Background: Chagas Disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi, with some of the most serious manifestations affecting the cardiovascular system. It is a chronic, stigmatizing condition, closely associated with poverty and affecting close to 6 million people globally. Although historically the disease was limited to endemic areas of Latin America recent years have seen an increasing global spread. In addition to the morbidity and mortality associated with the disease, the social and economic burdens on individuals and society are substantial. Often called the 'silent killer', Chagas disease is characterized by a long, asymptomatic phase in affected indivi duals. A pproximately 30% then go on develop chronic Chagas cardiomyopathy and other serious cardiac complications such as stroke, rhythm disturbances and severe heart failure. Methods: In a collaboration of the World Hearth Federation (WHF) and the Inter-American S ociety of Cardiology (IASC) a writing group consisting of 20 diverse experts on Chagas disease (CD) was convened. The group provided up to date expert knowledge based on their area of expertise. An extensive review of the literature describing obstacles to diagnosis and treatment Echeverría et al: WHF IASC Roadmap on Chagas Disease Art. 26, page 2 of 31 of CD along with proposed solutions was conducted. A survey was sent to all WHF Members and, using snowball sampling to widen the consultation, to a variety of health care professionals working in the CD global health community. The results were analyzed, open comments were reviewed and consolidated, and the findings were incorporated into this document, thus ensuring a consensus representation. Results: The WHF IASC Roadmap on Chagas Disease offers a comprehensive summary of current knowledge on prevention, diagnosis and management of the disease. In providing an analysis of 'roadblocks' in access to comprehensive care for Chagas disease patients, the document serves as a framework from which strategies for implementation such as national plans can be formulated. Several dimensions are considered in the analysis: healthcare system capabilities, governance, financing, community awareness and advocacy. Conclusion: The WHF IASC Roadmap proposes strategies and evidence-based solutions for healthcare professionals, health authorities and governments to help overcome the barriers to comprehensive care for Chagas disease patients. This roadmap describes an ideal patient care pathway, and explores the roadblocks along the way, offering potential solutions based on available research and examples in practice. It represents a call to action to decision-makers and health care professionals to step up efforts to eradicate Chagas disease.

show abstract

Section: Anti-trypanosomal Treatment During the Chronic Phasementioning

confidence: 99%

WHF IASC Roadmap on Chagas Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A prospective study analyzed BZN concentrations in blood samples and breastmilk from 12 lactating women receiving treatment for CD [116]. Median observed breastmilk BZN concentrations were low; the expected exposure to BZN of breastfeeding infants from mothers receiving BZN treatment was estimated at 12% of the mother's per kg dose, which is considered safe.…”

Section: Benznidazole During Pregnancy and Breastfeedingmentioning

confidence: 99%

Clinical and pharmacological profile of benznidazole for treatment of Chagas disease

Kratz

Bournissen

Forsyth

et al. 2018

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Chagas disease (CD) is one of the most neglected public health problems in the Americas, where <1% of the estimated 6 million people with the infection have been diagnosed and treated. The goal of treatment is to eliminate the parasite, decrease the probability of cardiomyopathy and other complications during the chronic stage of infection, and interrupt the cycle of disease transmission by preventing congenital infection. Currently, only benznidazole (BZN) and nifurtimox are recognized by the World Health Organization as effective drugs for treatment of CD. In this paper, we provide an overview of the clinical pharmacology of BZN. Areas covered: This review covers the historical background, chemistry, mechanism of action, pharmacokinetics, preclinical research, resistance, clinical research, toxicology, adverse effects, and current regulatory status of BZN. Expert commentary: Ongoing investigations aim to optimize BZN therapy by adjusting the current standard regimen or by combining BZN with new chemical entities. These studies are assessing alternatives that improve safety while maintaining or increasing the efficacy of BZN. Timely diagnosis and antitrypanosomal treatment are critical components of programs to eliminate CD as a public health problem, and can dramatically reduce the heavy burden of morbidity and mortality caused by the disease.

show abstract

“…2 Ese estudio enfoca dos temas a resaltar. El primero es el de las enfermedades huérfanas, es decir aquellas que no son adoptadas por la industria farmacéutica por no representar un incentivo económico para la fabricación y venta de medicamentos, sea por su baja frecuencia o porque afectan poblaciones de escasos recursos para comprar tales medicamentos.…”

unclassified

Drogas y lactancia. Un conflicto frecuente

Rossato¹

2015

Arch Argent Pediat

View full text Add to dashboard Cite

Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease

Abstract: ClinicalTrials.gov NCT01547533.

Cited by 31 publications

References 32 publications

WHF IASC Roadmap on Chagas Disease

WHF IASC Roadmap on Chagas Disease

Clinical and pharmacological profile of benznidazole for treatment of Chagas disease

Drogas y lactancia. Un conflicto frecuente

Contact Info

Product

Resources

About